KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Common Equity (2016 - 2025)

Jazz Pharmaceuticals has reported Common Equity over the past 16 years, most recently at $4.3 billion for Q4 2025.

  • Quarterly results put Common Equity at $4.3 billion for Q4 2025, up 5.49% from a year ago — trailing twelve months through Dec 2025 was $4.3 billion (up 5.49% YoY), and the annual figure for FY2025 was $4.3 billion, up 5.49%.
  • Common Equity for Q4 2025 was $4.3 billion at Jazz Pharmaceuticals, up from $4.0 billion in the prior quarter.
  • Over the last five years, Common Equity for JAZZ hit a ceiling of $4.3 billion in Q4 2025 and a floor of $2.7 billion in Q3 2022.
  • Median Common Equity over the past 5 years was $3.7 billion (2023), compared with a mean of $3.7 billion.
  • Biggest five-year swings in Common Equity: soared 35.22% in 2021 and later crashed 30.3% in 2022.
  • Jazz Pharmaceuticals' Common Equity stood at $4.0 billion in 2021, then fell by 22.18% to $3.1 billion in 2022, then grew by 21.11% to $3.7 billion in 2023, then grew by 9.55% to $4.1 billion in 2024, then increased by 5.49% to $4.3 billion in 2025.
  • The last three reported values for Common Equity were $4.3 billion (Q4 2025), $4.0 billion (Q3 2025), and $3.7 billion (Q2 2025) per Business Quant data.